WILLIAM HUGGINS: Open Payments
NPI 1316196157 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,673 in 69 payments from 12 companies in 2025. Trend: 2023 $2,596 · 2024 $2,154 · 2025 $1,673
Food & beverage: $1,673
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 16 | $590 |
| Insmed, Inc. | 8 | $206 |
| Aimmune Therapeutics, Inc. | 9 | $135 |
| Shionogi Inc | 7 | $116 |
| Gilead Sciences, Inc. | 5 | $106 |
| Merck Sharp & Dohme LLC | 5 | $106 |
| ABBVIE INC. | 4 | $98 |
| Paratek Pharmaceuticals, Inc. | 5 | $92 |
| Ferring Pharmaceuticals Inc. | 3 | $80 |
| Astellas Pharma US Inc | 3 | $67 |
Products named: DOVATO, Arikayce, CABENUVA, VOWST, Fetroja, PIFELTRO, NUZYRA, REBYOTA.
Industry payments across TX — which companies pay providers there.
